Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/PCC.17l02093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment.
Front Psychiatry
October 2024
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
For over seven decades, dopamine receptor 2 (D receptor) antagonists remained the mainstay treatment for neuropsychiatric disorders. Although it is effective for treating hyperdopaminergic symptoms, it is often ineffective for treating negative and cognitive deficits. Trace amine-associated receptor 1 (TAAR1) is a novel, pharmacological target in the treatment of schizophrenia and other neuropsychiatric conditions.
View Article and Find Full Text PDFExploring peptide dendrimers for intestinal lymphatic targeting: formulation and evaluation of peptide dendrimer conjugated liposomes for enhancing the oral bioavailability of Asenapine maleate.
Sci Rep
November 2024
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Article Synopsis
- Asenapine maleate (ASPM) is a second-generation antipsychotic approved for adult schizophrenia and bipolar disorder but suffers from low oral bioavailability (<2%) due to extensive first-pass metabolism in the liver.
- To improve ASPM's absorption, researchers developed nanoformulations using ligands like RGD and peptide dendrimers to target the intestinal lymphatic system.
- Various techniques, including solid phase peptide synthesis and high-performance chromatography, were used to create and characterize liposomal formulations, and in vitro and in vivo studies were conducted to assess their effectiveness and pharmacokinetics in rats.
Comorbid ADHD and schizophrenia and the use of psychostimulants: a scoping review protocol.
BMJ Open
October 2024
School of Medicine, The University of Manchester, Manchester, UK.
Article Synopsis
- Schizophrenia and ADHD are serious mental health disorders that may share some genetic and symptomatic links, but there’s limited guidance on treating patients with both conditions, specifically regarding psychostimulants.
- This scoping review will systematically gather and analyze existing literature on the effects of psychostimulants for these patients, using a structured framework and screening multiple databases along with grey literature.
- The review aims to fill the gap in high-quality evidence for healthcare providers, helping to inform better treatment decisions and improve outcomes for patients with comorbid schizophrenia and ADHD.
Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update.
J Clin Med
September 2024
3rd Department of Psychiatry, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Schizophrenia is a chronic psychotic disorder comprising positive symptoms, negative symptoms, and cognitive deficits. Negative symptoms are associated with stigma, worse functional outcomes, and a significant deterioration in quality of life. Clinical diagnosis is challenging despite its significance, and current treatments offer little improvement in the burden of negative symptoms.
View Article and Find Full Text PDFCannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission.
Pharmacol Biochem Behav
December 2024
Department of Neurosciences and Behavioral Sciences, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Basic and Oral Biology, School of Dentistry of Ribeirão Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
Individuals with schizophrenia (SCZ) often present sensorimotor gating impairments that can be investigated by the prepulse inhibition test (PPI). PPI disruption can be mimicked experimentally with psychostimulants such as amphetamine and attenuated/reversed by antipsychotics. Cannabidiol (CBD), the main non-psychotomimetic component of the Cannabis sativa plant, produces antipsychotic-like effects in clinical and preclinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!